Severe acute respiratory syndrome coronavirus 2 infection does not worsen the course of inflammatory bowel disease in the long term.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
31
7
2023
pubmed:
28
7
2023
entrez:
28
7
2023
Statut:
ppublish
Résumé
The long-term outcome of inflammatory bowel disease (IBD) patients after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is under investigation. To assess, in a prospective study, whether a recent SARS-CoV-2 infection increases the risk of IBD relapse within 12 months. From March to April 2021, all IBD patients with recent (<2 months) SARS-CoV-2 infection (Cases) were enrolled. For each enrolled Case, four IBD Controls with no history of infection were considered. Clinical course of IBD was recorded for 12 months. Inclusion criteria: well defined diagnosis of IBD; age ≥18 and ≤85 years; 12-month follow-up; consent. Exclusion criteria: incomplete data; SARS-CoV-2 infection after enrollment. Additional inclusion criteria: recent SARS-CoV-2 infection for Cases; no history of SARS-CoV-2 infection for Controls. Data expressed as median [range]. Statistical analysis: Student-t-Test, Mann-Whitney U-test, χ2 test, multivariate logistic regression model [odds ratio (95% confidence interval)], Kaplan-Meier curves. One hundred forty-three IBD patients were enrolled. The analysis included 118 patients (22 met the exclusion criteria, three lost at follow-up): 29 (24.6%) Cases and 89 (75.4%) Controls. Demographic and clinical characteristics were comparable between groups. During the 12-month study, the frequency of IBD relapse was comparable between Cases and Controls [8 (27%) vs 19 (21%); P = 0.65]. At univariate analysis, SARS-CoV-2 infection was not a risk factor for IBD relapse within 12 months [1.5 (0.6-3.9); P = 0.34]. At multivariate analysis, IBD activity at baseline was the only risk factor for relapse [3.2 (1.1-9.1); P = 0.03]. Kaplan-Meier curves showed that survival from IBD relapse was comparable between Cases and Controls (P = 0.33). In a prospective 12-month study, a recent SARS-CoV-2 infection did not increase the risk of clinical relapse of IBD in the long term.
Sections du résumé
BACKGROUND
The long-term outcome of inflammatory bowel disease (IBD) patients after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is under investigation.
AIM
To assess, in a prospective study, whether a recent SARS-CoV-2 infection increases the risk of IBD relapse within 12 months.
METHODS
From March to April 2021, all IBD patients with recent (<2 months) SARS-CoV-2 infection (Cases) were enrolled. For each enrolled Case, four IBD Controls with no history of infection were considered. Clinical course of IBD was recorded for 12 months. Inclusion criteria: well defined diagnosis of IBD; age ≥18 and ≤85 years; 12-month follow-up; consent. Exclusion criteria: incomplete data; SARS-CoV-2 infection after enrollment. Additional inclusion criteria: recent SARS-CoV-2 infection for Cases; no history of SARS-CoV-2 infection for Controls. Data expressed as median [range]. Statistical analysis: Student-t-Test, Mann-Whitney U-test, χ2 test, multivariate logistic regression model [odds ratio (95% confidence interval)], Kaplan-Meier curves.
RESULTS
One hundred forty-three IBD patients were enrolled. The analysis included 118 patients (22 met the exclusion criteria, three lost at follow-up): 29 (24.6%) Cases and 89 (75.4%) Controls. Demographic and clinical characteristics were comparable between groups. During the 12-month study, the frequency of IBD relapse was comparable between Cases and Controls [8 (27%) vs 19 (21%); P = 0.65]. At univariate analysis, SARS-CoV-2 infection was not a risk factor for IBD relapse within 12 months [1.5 (0.6-3.9); P = 0.34]. At multivariate analysis, IBD activity at baseline was the only risk factor for relapse [3.2 (1.1-9.1); P = 0.03]. Kaplan-Meier curves showed that survival from IBD relapse was comparable between Cases and Controls (P = 0.33).
CONCLUSION
In a prospective 12-month study, a recent SARS-CoV-2 infection did not increase the risk of clinical relapse of IBD in the long term.
Identifiants
pubmed: 37505974
doi: 10.1097/MEG.0000000000002554
pii: 00042737-202309000-00003
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
948-954Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, et al.; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG- IBD study. Gut 2020; 69:1213–1217.
Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Corticosteroids, but not TNF antagonists are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an International Registry. Gastroenterology 2020; 159:481–491.e3.
Norsa L, Prantera C, Indriolo A, Sansotta N, D’Antiga L, Callegaro A. Asymptomatic SARS-CoV-2 infection in patients with inflammatory bowel disease under biologic treatment. Gastroenterology 2020; 159:2229–2231.
Kumric M, Ticinovic Kurir T, Martinovic D, Marin Zivkovic D, Bozic J. Impact of the COVID-19 pandemic on inflammatory bowel disease patients: a review of the current evidence. World J Gastroenterol 2021; 27:3748–3761.
Sultan K, Mone A, Durbin L, Khuwaja S, Swaminath A. Review of inflammatory bowel disease and COVID-19. World J Gastroenterol 2020; 26:5534–5542.
Magro F, Rahier JF, Abreu C, MacMahon E, Hart A, van der Woude CJ, et al. Inflammatory bowel disease management during the COVID-19 outbreak: the 10 do’s and don’ts from the ECCO-COVID task force. J Crohns Colitis 2020; 14:S798–S806.
D’Amico F, Danese S, Peyrin-Biroulet L. Systematic review on IBD patients with COVID-19: it is time to take stock. Clin Gastroenterol Hepatol 2020; 18:2689–2700.
Scucchi L, Neri B, Sarmati L, Mossa M, Sena G, Massoud R, et al. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease. Eur Rev Med Pharmacol Sci 2021; 25:2418–2424.
Mossa M, Neri B, Montesano L, Salvatori S, Marafini I, Scucchi L, et al. SARS-CoV-2 IgG seroprevalence in IBD patients treated with biologics: first vs. second pandemic wave in a prospective study. Eur Rev Med Pharmacol Sci 2022; 26:3787–3796.
Zhanga M, Zhoua Y, Lia H, Peng Y, Qiu P, Shi X, et al. COVID-19: gastrointestinal symptoms from the view of gut-lung axis. Eur J Gastroenterol Hepatol 2021; 33:610–612.
Burgueño JF, Reich A, Hazime H, Quintero MA, Fernandez I, Fritsch J, et al. Expression of SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in the gut of patients with IBD. Inflamm Bowel Dis 2020; 26:797–808.
Effenberger M, Grabherr F, Mayr L, Schwaerzler J, Nairz M, Seifert M, et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut 2020; 69:1543–1544.
Papa A, Scaldaferri F, Covino M, Tursi A, Furfaro F, Mocci G, et al. Impact of SARS-CoV-2 infection on the course of inflammatory bowel disease in patients treated with biological therapeutic agents: a case-control study. Biomedicines 2022; 10:843–853.
Gomollòn F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al.; ECCO. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: diagnosis and medical management. J Crohns Colitis 2017; 11:3–25.
Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al.; European Crohn’s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo–anal pouch disorders. J Crohns Colitis 2017; 11:649–670.
Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55:749–753.
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalcylic acid therapy for mildly to moderately active ulcerative colitis. N Eng J Med 1987; 317:1625–1629.
Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980; 315:514514.
Wetwittayakhlang P, Albader F, Golovics PA, et al. Clinical outcomes of COVID-19 and impact on disease course in patients with inflammatory bowel disease. Can J Gastroenterol Hepatol 2021; Article ID 7591141:9.
Nowak JK, Lindstrøm JC, Kalla R, Ricanek P, Halfvarson J, Satsangi J. Age, inflammation, and disease location are critical determinants of intestinal expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in inflammatory bowel disease. Gastroenterology 2020; 159:1151–1154.e2.
Monteleone G, Ardizzone S. Are patients with inflammatory bowel disease at increased risk for covid-19 infection? J Crohns Colitis 2020; 14:1334–1336.
Singh AK, Jena A, Kumar-M P, Sharma V, Sebastian S. Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. United European Gastroenterol J 2021; 9:159–176.
Attauabi M, Poulsen A, Teede K, Pedersen N, Larsen L, Jess T, et al. Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease – a Danish prospective population-based cohort study. J Crohns Colitis 2021; 15:540–550.
Maconi G, Bosetti C, De Monti A, Boyapati RK, Shelton E, Piazza N, et al. Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population Dig Liv Dis 2021; 53:263–270.
Ungaro RC, Brenner EJ, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021; 70:725–732.
Lukin DJ, Funez-dePagnier G, Lima S, Lai D, Duenas-Bianchi L, Ahmed W, et al. No durable impact of COVID-19 on intestinal disease activity in subjects with IBD. Clin Gastroenterol Hepatol 2021; 19:2312–2314.e3.
Torres J, Caprioli F, Katsanos KH, Lobatón T, Micic D, Zerôncio M, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases. J Crohns Colitis 2016; 10:1385–1394.